CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Cytomx Therapeutics, Inc.  (CTMX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
 

CTMX's Revenue Year on Year Growth by Quarter and Year

Cytomx Therapeutics,'s Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
CTMX Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 6.27 -1.94 0.00
III Quarter September - 3.45 1.94 0.00
II Quarter June 8.75 3.09 0.00 0.00
I Quarter March 11.65 2.22 0.00 0.00
FY   20.40 15.03 - -

Financial Statements
Cytomx Therapeutics,'s second quarter 2017 Revenue $ 8.75 millions CTMX's Income Statement
Cytomx Therapeutics,'s second quarter 2016 Revenue $ 3.09 millions Quarterly CTMX's Income Statement
CTMX's Growth by Division See CTMX's Growth by Segment

CTMX Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - - - -
III Quarter September - 77.84 % - -
II Quarter June 183.24 % - - -
I Quarter March 424.77 % - - -
FY   - - - -



CTMX Revenue Growth Comment
Cytomx Therapeutics, Inc. reported Revenue surge of 183.24% year on year in the second quarter, to $ 8.75 millions, this is lower than Cytomx Therapeutics, Inc.'s recent average Revenue surge of 228.4%.

Looking into second quarter results within Biotechnology & Drugs industry 9 other companies have achieved higher Revenue growth. While Cytomx Therapeutics, Inc.' s Revenue doubling of 183.24% ranks overall at the positon no. 140 in the second quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #10
Healthcare Sector #36
Overall #140
Revenue Y/Y Growth Statistics
High Average Low
424.2 % 228.4 % 78.13 %
(Mar 31 2017)   (Sep 30 2016)

You need to upgrade your Flash Player

Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CTMX's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CTMX's Competitors
Revenue Growth for Cytomx Therapeutics,'s Suppliers
Revenue Growth for CTMX's Customers

You may also want to know
CTMX's Annual Growth Rates CTMX's Profitability Ratios CTMX's Asset Turnover Ratio CTMX's Dividend Growth
CTMX's Roe CTMX's Valuation Ratios CTMX's Financial Strength Ratios CTMX's Dividend Payout Ratio
CTMX's Roa CTMX's Inventory Turnover Ratio CTMX's Growth Rates CTMX's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Jun 30 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2017
Zogenix, Inc.  241.24 %$ 241.236 millions
Steadymed Ltd.  239.36 %$ 239.362 millions
Arbutus Biopharma Corp  236.25 %$ 236.246 millions
Apollo Medical Holdings, Inc.  236.05 %$ 236.054 millions
Neos Therapeutics, Inc.  230.57 %$ 230.572 millions
Inovio Pharmaceuticals, Inc.  229.03 %$ 229.027 millions
Chemocentryx, Inc.  219.75 %$ 219.750 millions
Ptc Therapeutics, Inc.  206.80 %$ 206.800 millions
Bellicum Pharmaceuticals, Inc.  203.96 %$ 203.960 millions
Cti Biopharma Corp.  201.93 %$ 201.929 millions
Orexigen Therapeutics, Inc.  199.78 %$ 199.782 millions
Enzon Pharmaceuticals, Inc.  198.20 %$ 198.195 millions
Cytomx Therapeutics, Inc.  182.87 %$ 182.870 millions
Regenxbio Inc.  176.29 %$ 176.295 millions
Hci Viocare  175.23 %$ 175.234 millions
American Cryostem Corp  172.48 %$ 172.478 millions
Exact Sciences Corp  172.11 %$ 172.108 millions
Ionis Pharmaceuticals Inc  170.74 %$ 170.736 millions
Novavax Inc  168.74 %$ 168.743 millions
Invitae Corp  156.87 %$ 156.872 millions
Biolargo, Inc.  156.45 %$ 156.446 millions
Lifestyle Medical Network, Inc.  153.16 %$ 153.158 millions
Rewalk Robotics Ltd.  145.65 %$ 145.655 millions
Viewray, Inc.  133.44 %$ 133.445 millions
Second Sight Medical Products Inc  115.62 %$ 115.622 millions
American Cannabis Company, Inc.  114.76 %$ 114.760 millions
Novocure Ltd  114.16 %$ 114.164 millions
Geovax Labs, Inc.  111.77 %$ 111.774 millions
Kite Pharma, Inc.  109.64 %$ 109.635 millions
U.s. Stem Cell, Inc.  104.34 %$ 104.345 millions